US Patent

US10010537 — Clevidipine emulsion formulations containing antimicrobial agents

Formulation · Assigned to Chiesi Farmaceutici SpA · Expires 2031-10-10 · 5y remaining

Vulnerability score 31/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects formulations of clevidipine, specifically Cleviprex, that contain antimicrobial agents to reduce microbial growth.

USPTO Abstract

Pharmaceutical formulations comprising clevidipine and an antimicrobial agent exhibit a reduced propensity for microbial growth and provide increased convenience to health care workers administering clevidipine-containing formulations to patients.

Drugs covered by this patent

Cleviprex (CLEVIDIPINE) · Chiesi

Patent Metadata

Patent number: US10010537
Jurisdiction: US
Classification: Formulation
Expires: 2031-10-10
Drug substance claim: No
Drug product claim: Yes
Assignee: Chiesi Farmaceutici SpA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.